Zoledronic acid (ZA) is a nitrogen-containing bisphosphonate with antitumor activity used to treat patients with malignant diseases. ZA treatment induces, as a side effect, inflammatory responses, which are accompanied by expansion of cd T cells. In our study, we analyzed the function and differentiation of monocyte-derived immature and lipopolysaccharide (LPS)-stimulated dendritic cells (moDCs) treated with different ZA concentrations, which are achieved in patients. We found that moDC activation with TLR4 ligand LPS is modulated by ZA. The expression of maturation markers was diminished with increasing ZA levels upon LPS activation. The migratory capacity, interleukin-12 secretion and generation of cytotoxic-T-cell responses were reduced at higher ZA levels. Increasing ZA concentrations downregulated nuclear factor-jB family members and interferon-regulatory factor (IRF)-3. Surprisingly, in immature moDCs, low ZA concentrations caused upregulation of RelB, c-Rel, IRF-3 and IRF-8. We conclude that ZA concentrations used to treat patients have inhibitory effects on DC activation. This might lead to immunosuppression or result in infectious complications.
Introduction
Nitrogen-containing bisphosphonates (NBPs) have recently been reported to mediate antitumor effects. [1] [2] [3] The application of zoledronic acid (ZA) achieved promising results in the treatment of skeletal-related events in patients with malignancies. [1] [2] [3] [4] Bisphosphonates (BPs) were first applied in the therapy of tumor-induced bone-related diseases. 3 Currently these compounds are used in adjuvant setting in patients with breast cancer to prevent metastatic disease. BPs display their properties as inhibitors of bone resorption 5 as they are analogues of pyrophosphate, an inhibitor of bone mineralization. ZA belongs to the group of cyclic amino-BPs, which represent the most evolved NBPs and show a greatly enhanced antiresorptive potency in comparison to BPs of the first generation.
ZA inhibits the enzyme farnesyl pyrophosphate synthase which plays an important role in the mevalonate pathway. 4 This results in the reduced prenylation of a variety of proteins with mediator functions in signalling cascades, such as Ras. 2 Owing to its interference with different cellular mechanisms, ZA application causes various side effects. ZA-induced hypocalcemia, nausea, skeletal pain, nephrotic symptoms and signs of acute-phase reaction have been reported. 6 Tumor necrosis factor (TNF)-a, an initiator of acute-phase reactions, stimulates the activation of dendritic cells. 7, 8 Several studies have stressed the influence of ZA on the activation of gd T cells 9, 10 in patients with acute-phase reactions. In these reports it was demonstrated that gd T cells may mediate the observed antitumor activity of BPs. In our study, we analyzed the effects of ZA on the differentiation and function of monocyte-derived dendritic cells (moDCs). DCs are recognized as the most important antigen-presenting cells (APCs) capable of initiating and maintaining primary immune responses. They usually reside in the tissues of almost all organs. After having experienced contact with pathogens, DCs migrate to afferent lymphoid organs and undergo phenotypic and functional changes characterized by the upregulated expression of costimulatory and human lymphocyte antigen molecules as well as the increased secretion of cytokines and chemokines. In the lymph nodes, they present previously captured antigens to T-lymphocytes, and activate the adaptive immune system by generating antigen-specific responses. 11 The differentiation and activation of DCs are known to be influenced through different receptor types among which Toll-like receptors (TLRs) play a crucial role in the subsequent immune outcome. 12 TLRs belong to the family of pattern recognition receptors, which recognize antigens with specific structures. TLR4, for instance, recognizes lipopolysaccharides (LPS) as part of the Gram-negative bacterial cell wall. 13 
Materials and methods

Reagents
Cells were cultured in RP10 medium (RPMI 1640 with glutamax-I, supplemented with 10% heat-inactivated fetal calf serum and antibiotics, all purchased from Invitrogen (Karlsruhe, Germany)). ZA (Zometa) and human recombinant granulocyte macrophage-colony-stimulating factor (GM-CSF) (Leukine, Liquid Sargramostim) were obtained from Novartis (Nü rnberg, Germany). Human recombinant interleukin-4 (IL-4) was purchased from R&D Systems (Wiesbaden, Germany) and LPS was from Sigma-Aldrich (Deisenhofen, Germany).
Generation of DCs from adherent peripheral blood mononuclear cells
DCs were generated from peripheral blood monocytes as described previously. 14, 15 To analyze the effects of ZA, different ZA concentrations (0.001, 0.01, 0.05, 0.1, 0.2, 0.5, 1 and 5 mg/ml) were added to the cultured cells every other day from the first day of culture. For maturation, DCs were cultured with 100 ng/ml LPS for 15 min, 2 h or 24 h. Cells were harvested after 7 days of culture and used for further experiments.
Flow cytometry analysis
Cells were stained using fluorescein isothiocyanate (FITC)--or phycoerythrin (PE)-conjugated mouse monoclonal antibodies against CD1a (Dako Diagnostika, Hamburg, Germany); CD14, HLA-DR and CD54 (BD-Biosciences, Heidelberg, Germany); CD40 and CD86 (BD-PharMingen, Hamburg, Germany); CD80 and CD83 (Immunotech, Marseille, France); DC-SIGN (R&D Systems, Wiesbaden, Germany) and mouse immunoglobulin (Ig)G isotype control (BD Biosciences). Cells were analyzed on a FACSCalibur cytometer (BD Biosciences). To calculate the percentage of positive cells, a proportion of 1% false-positive events was accepted in the negative control samples throughout. The numbers of apoptotic and necrotic cells were enumerated through staining of DCs with Annexin V and propidium iodide using the Annexin-V-FLUOS Staining Kit (Roche Diagnostics, Mannheim, Germany) according to the manufacturer's instructions. 16 
Migration assay
DCs (2 Â 10 5 ) were seeded into a transwell chamber (8 mm, BD Falcon, BD Biosciences) in a 24-well plate and migration was induced through chemokine-CC motif-ligand 19 (CCL19/MIP3b, 100 mg/ml; R&D Systems, Wiesbaden, Germany). After 16 h, migrated cells were analyzed by counting gated DCs for a time interval of 60 s on a FACSCalibur cytometer. 15 
Cytokine determination
Mature DCs were generated as described earlier. Supernatants of the cultures were harvested on day 7 and used for cytokine determination. Cytokine concentrations were measured with commercially available two-site sandwich enzyme-linked immunosorbant assay (ELISA) from Beckmann Coulter (Hamburg, Germany; IL-10 and IL-12), according to the manufacturer's instructions.
Induction of antigen-specific Cytotoxic T Lymphocyte response using the peptide E75 from Her-2/neu
The induction of Her-2/neu-specific CTL was performed as described previously. 17 LPS-activated DCs (5 Â 10 5 ), generated with or without 1 mg/ml ZA, were pulsed with 50 mg/ml E75 for 2 h, washed and incubated with 2.5 Â 10 6 autologous nonadherent cells with or without the addition of anti-IL-10 (10 mg/ ml). After 7 days of culture, cells were re-stimulated with autologous peptide-pulsed nonadherent cells and 1 ng/ml IL-2 was added on days 1, 3 and 5. On day 6, cells were restimulated again and treated with IL-2 as described above. The cytolytic activity of induced CTL was analyzed on day 5 after the second re-stimulation in a standard 51 Cr-labelled release assay.
CTL assay
The standard 51 Cr-labelled release assay was performed as described. 17 Target cells (LPS-activated DCs or K562) were pulsed with 50 mg/ml E75 peptide or HIV peptide (used as an irrelevant control) for 2 h and labelled with standard [ ) were transferred to a well of a round-bottom 96-well plate. Varying numbers of CTL were added to reach a final volume of 200 ml and were incubated for 4 h at 371C. Supernatants (50 ml/well) were harvested and counted in a beta-plate counter. The percentage of specific lysis was calculated as follows: 100 Â (experimental release-spontaneous release/maximal release-spontaneous release). Spontaneous release and maximal release were determined in the presence of either medium or 1% Triton X-100, respectively.
Polyacrylamide gel electrophoresis and Western blotting
Nuclear extracts and whole-cell lysates were prepared from DCs as described previously. 14, 15 Protein concentrations of wholecell lysates were determined using a BCA Protein Assay kit (Pierce, Perbio Science, Bonn, Germany).
For protein detection, Western blotting was performed as described previously.
14 Ponceau S staining of the membrane was performed to confirm that equal amounts of protein had been loaded onto the gel. The blots were probed with antibodies for RelB (C-19, rabbit polyclonal), c-Rel (B-6, mouse monoclonal), IRF-3 (C-20, goat polyclonal), IRF-8 (C-19, goat polyclonal) (all purchased from Santa Cruz Biotechnology, Santa Cruz, Heidelberg, Germany), phospho-p38 (Thr180/ Tyr182, rabbit polyclonal), p38 mitogen-activated protein (MAP) kinase (rabbit polyclonal), phospho-p42/44 (Thr202/ Tyr204, rabbit polyclonal), Akt (rabbit polyclonal) (all from Cell Signaling Technology, New England Biolabs, Frankfurt, Germany) and ERK1 (C-16, rabbit polyclonal) and MyD88 (N-19, goat polyclonal) (both from Santa Cruz). 15 
Results
ZA affects the expression of DC surface markers and DC maturation
To evaluate the effects of pharmacological concentrations of ZA on the immunogenicity of moDCs, surface marker molecules were analyzed ( Figure 1 ). Pretreatment of both mature and immature DCs with ZA concentrations between 1 and 5 mg/ml led to a decreased expression of the DC-specific marker CD1a and HLA-DR molecules (Figure 1a and b). The levels of the maturation marker CD83, 18 the costimulatory molecules CD80 and CD86 and of DC-SIGN, a C-type lectin that mediates adhesion with T cells by stabilizing the DC/T cell contact zone, were downregulated during the exposure to increasing ZA concentrations in LPS-activated moDCs (Figure 1b and c) . In a similar way, ZA modulated the expression of CD40 and the integrin CD54 (data not shown). 19 In immature and mature DCs, low ZA concentrations (up to 0.5 mg/ml) did not change or slightly increased the expression of the cell surface marker HLA-DR and, in mature DCs, the level of the costimulatory molecule CD86. The expression of the monocyte-specific surface molecule CD14 was not altered by ZA application and remained at very low levels. These results were obtained in a series of at least three independent experiments.
Altered migratory capacity in DCs exposed to ZA As shown in Figure 2 , LPS-matured moDCs acquired the capability to migrate toward a CCL19/MIP-3b gradient. ZA concentrations higher than 0.2 mg/ml reduced the migratory capacity of mature DCs. Interestingly, migration of DCs was enhanced when the cells were treated with ZA concentrations up to 0.2 mg/ml. 
ZA modifies cytokine secretion
An increased cytokine secretion, after receiving maturation stimuli, displays a significant function of DCs. 18 LPS stimulation of moDCs raised the levels of IL-12, which induces T H 1 immune responses. IL-12 secretion was inhibited on ZA addition at a concentration of 5 mg/ml (Figure 3a) . ZA concentrations up to 0.1 mg/ml had no visible effect on the secretion of the inhibitory Zoledronic acid inhibits dendritic cell function A Bringmann et al cytokine IL-10, whereas concentrations of 0.5 and 1 mg/ml upregulated its production by DCs. The application of 5 mg/ml completely inhibited IL-10 secretion (Figure 3b) . Thus, the observed inhibition of DC activation and function is in part mediated by IL-10. The results are consistent in three independent experiments.
ZA-treated DCs have a reduced ability to elicit cytotoxic T-cell responses
A major characteristic of activated DCs is the ability to induce primary specific CTL responses resulting in lysis of recognized target cells. E75-specific CTLs, which were induced by LPSactivated DCs generated in the presence of 1 mg/ml ZA, showed an impaired capability to lyse DCs pulsed with the Her-2/neu peptide (Figure 4a and b) . E75-specific lysis was enhanced considerably when CTLs were induced in the presence of anti-IL-10 antibody. The percentage of specific lysis, however, did not reach the level of CTLs induced in the presence of anti-IL-10 with DCs generated without ZA.
High ZA concentrations induce apoptosis in DCs
Recently, it was shown that ZA can induce apoptotic cell death in different cell lines. 20 To analyze its effect on DCs, Annexin V and propidium iodide staining of generated cells pretreated with Zoledronic acid inhibits dendritic cell function A Bringmann et al different ZA concentrations was performed. As demonstrated in Figure 5 , low concentrations of 0.01-0.2 mg/ml had no effect on the viability of DCs. The percentage of Annexin V-positive and thus apoptotic cells amounted to 5-7% (Figure 5a) . Numerical values of Annexin V and propidium iodide double positive and thus necrotic cells were 11-14% (Figure 5b ). However, ZA concentrations of 0.5 mg/ml and higher led to an enhanced rate of Annexin V-positive and Annexin V/propidium iodide double positive cells with about 25% apoptotic cells at the highest administered concentration of 5 mg/ml ZA and up to 45% necrotic cells. Thus, these results demonstrate that the inhibitory effect of ZA at higher concentrations are in part due to the induction of apoptotic cell death.
Effects of ZA on DC intracelular signalling cascades
Differentiation, cell growth and apoptosis are mediated through complex signalling cascades. As shown previously, members of the nuclear factor-kB (NF-kB) family of transcription factors play an important role in DC differentiation and response to inflammatory stimuli. 21 The exposure of immature DCs during differentiation to ZA concentrations of 0.1 and 0.5 mg/ml caused an increase of nuclear-localized c-Rel and RelB (Figure 6a ). In contrast, in LPS-stimulated DCs, ZA addition resulted in a reduced localization of both NF-kB family members.
Another group of transcription factors that are involved in the DC function are interferon-regulatory factors (IRFs). IRF-8 and IRF-3 were both shown to be involved in LPS-induced TLR4 signalling. We found that the application of low doses of ZA (0.1 and 0.5 mg/ml, respectively) increased, in line with the results above, the amount of nuclear IRF-8 and IRF-3 in immature DCs. However, IRF-3 and IRF-8 levels were diminished with increasing ZA concentrations in mature DCs treated with the TLR4 stimulus LPS (Figure 6a) .
To analyze the involvement of upstream located members of signalling pathways, key enzymes of the MAP kinase cascade, p38 and ERK, were analyzed (Figure 6b ). MAPKs p38 and ERK were shown to be important in the development and maturation of DCs. [22] [23] [24] Incubation of DCs with increasing ZA concentrations up to 1 mg/ml enhanced phosphorylation and thus activation of ERK in both immature and LPS-stimulated DCs. In a similar way, phosphorylation of p38 augmented with increasing ZA concentrations, which was more pronounced in immature DCs. However, in contrast to the expression of ERK, which, in this case, can serve as a loading control, expression of p38 was enhanced with increasing ZA concentrations.
The myeloid differentiation primary response gene 88 (MyD88) plays an important role in TLR4 signalling. This adaptor is recruited to the TLR4-MD2 complex upon ligand binding and interacts specifically with the IL-1 receptorassociated kinases (IRAKs) IRAK1 and IRAK4, which activate the MAP kinase cascade and NF-kB. 21, 25 The analysis of lysates from immature and mature DCs for MyD88 expression showed downregulation with increasing levels of the BPs in comparison with the loading control Akt (Figure 6a ).
All Western blots were performed at least three times.
Discussion
In this study, we analyzed the effects of ZA on the generation and function of monocyte-derived DCs. DC differentiation in vitro was triggered by stimulation with IL-4 and granulocyte macrophage-CSF and resulted in a DC-specific phenotype. In DCs from several donors, we observed that treatment with a high dose of ZA, which is usually achieved in patients, induced inhibitory effects and caused downregulation of HLA and costimulatory molecules. Maturation of DCs in vitro into competent stimulatory APCs can be triggered by LPS. As a component of the cell wall of Gram-negative bacteria, LPS is released during bacterial infections and interacts with the TLR-MD2 complex at the cell surface. 13, 21, 26 LPS stimulation alters different DC properties, including their immunogenicity and lifespan. In this study, ZA treatment of LPS-activated DCs was accompanied by downregulation of the costimulatory molecule CD80 as well as CD83 and CD40, which was shown to promote DC maturation upon its binding by CD40 ligand expressed on T cells. 18 We obtained a similar profile for the adhesion molecules CD54 and DC-SIGN, which mediate interactions between T-lymphocytes and DCs. 18, 19 The secretion of IL-12 27 followed the repeatedly seen pattern of being enhanced at low ZA concentrations and diminished at 1 mg/ml ZA. This result is in line with the other observed effects that show a slight activation at low ZA concentrations and inhibition at high ZA levels. The analysis of the inhibitory Zoledronic acid inhibits dendritic cell function A Bringmann et al cytokine IL-10 also showed a maximum release, however, the peak was observed between 0.5 and 1 mg/ml and thus at higher ZA concentrations as usual. In our opinion, this hinted at the possibility that IL-10 is partly responsible for the inhibitory properties of ZA at higher concentrations. This hypothesis was supported by our finding that the ability of DCs to induce specific CTLs, which is strongly reduced by 1 mg/ml ZA, was partly restored through the administration of an anti-IL-10 antibody.
Analysis of another feature of activated DC, the migration toward a CCL19/MIP-3b gradient, again resulted in an enhanced activity at low but reduced activity at high ZA concentrations.
During maturation of moDCs, these cells undergo various changes in phenotype and function. These processes include the regulation of several genes. LPS activation of DCs influences the MyD88-dependent and MyD88-independent pathway. 21, 25 Both are initiated through binding of LPS and dimerization of TLR4. The MyD88-dependent pathway results in the rapid release of NF-kB. [28] [29] [30] Members of the NF-kB family control different aspects of DC development and function, RelB having a particularly relevant role. 11, 18, 31 The MyD88-independent pathway leads to the activation of IRFs and an increased expression of IFN-inducible genes. 29, 32 The MyD88-independent pathway results in the secretion of IFN-b and a delayed NF-kB release 33 IRFs are important in DC stimulation as they trigger the maturation process. Additionally, IRF-3 mediates endotoxic shock in response to LPS. 34 IRF-8 is a hematopoietic transcription factor, which affects cell growth and the function of immune cells such as macrophages and DCs. 35, 36 It is involved in the development and trafficking of Langerhans cells and dermal DCs, as it induces the expression of CCR6 and CCR7. 37 Furthermore, IRFs and NF-kB members control the production of IL-12. 38 Both families of transcription factors and upstream-located molecules of their signalling cascades cooperate to obtain an optimal immune response toward pathogens. In our study, we found that pretreatment of DCs with ZA inhibits the expression of IRF-3 and IRF-8 in LPS-activated DCs. Furthermore, ZA reduced the level of nuclear-localized RelB and c-Rel in mature DCs. These effects could be due to the diminished expression of the MyD88 molecule in ZA-treated cells. Analysis of the MAPK pathways revealed a slight activation of ERK, detectable as its phosphorylation, in ZA-treated cells. Phosphorylation of p38 was increased in immature DCs and in LPS-treated cells, where it was accompanied by a higher expression of the p38 protein.
At first, the increase in both p38 expression and ERK phosphorylation seemed to be surprising and not in line with the other results that showed inhibitory effects of 1 mg/ml ZA. However, it has been demonstrated repeatedly that IL-10 production depends on ERK activation, 39, 40 which supports our findings.
Altogether, our results demonstrate that application of highdose ZA displays inhibitory effects on DC differentiation and activation. BPs are now widely used to treat patients with malignant-metastatic disease in case of hypercalcemia or in the presence of bone leasions. In addition, they are prescribed to patients with multiple myeloma, osteoporosis or in adjuvant setting in patients with breast cancer that requires long-term application of these compounds. According to our results, this might result in a patient-dependent inhibition of DC function and thus in immunosuppression, as higher concentrations used in our study are usually achieved in treated patients. These immunosuppressive effects may have a negative impact on the tumor surveillance or control of minimal residual disease, or promote infectious complications.
